mRNA Therapeutics CDMO Global Market Report 2025

Description

An mRNA therapeutics CDMO, or messenger ribonucleic acid therapeutics contract development and manufacturing organization, is a specialized third-party provider that offers comprehensive support for the research, development, and scalable production of mRNA-based therapeutic agents under contractual agreements with pharmaceutical or biotechnology companies. These organizations are vital in accelerating time-to-market, ensuring regulatory compliance, and providing flexible manufacturing capacity for mRNA therapeutic pipelines.

The primary types of services offered by mRNA therapeutics CDMOs include development services, manufacturing services, and laboratory services. Development services encompass end-to-end support for the design, optimization, and scale-up of mRNA-based therapeutics, including synthesis, formulation, analytical development, and process development tailored to the specific needs of each client. These therapeutics are applied to treat indications such as infectious diseases, metabolic and genetic disorders, and cardiovascular and cerebrovascular conditions. Applications include viral vaccines, protein replacement therapies, and cancer immunotherapies, and the end users of these services include pharmaceutical companies, biotechnology firms, academic institutions, and research organizations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The mRNA therapeutics CDMO market research report is one of a series of new reports from The Business Research Company that provides mRNA therapeutics CDMO market statistics, including mRNA therapeutics CDMO industry global market size, regional shares, competitors with a mRNA therapeutics CDMO market share, detailed mRNA therapeutics CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the mRNA therapeutics CDMO industry. This mRNA therapeutics CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mRNA therapeutics CDMO market size has grown rapidly in recent years. It will grow from $4.24 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth during the historic period can be attributed to the increasing demand for rapid vaccine development, rising public and private funding for mRNA research, a growing incidence of infectious diseases, expanding pharmaceutical outsourcing practices, and an intensified global focus on pandemic preparedness.

The mRNA therapeutics CDMO market size is expected to see rapid growth in the next few years. It will grow to $7.40 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to the accelerating focus on personalized medicine, rising demand for rapid response platforms against emerging diseases, increasing healthcare expenditure in developing regions, growing government incentives for domestic manufacturing, and heightened interest in applying mRNA technologies to non-infectious diseases. Major trends during this period include advancements in lipid nanoparticle delivery technologies, increased automation in manufacturing processes, broader adoption of modular and continuous manufacturing platforms, improvements in cold chain logistics infrastructure, and the rising integration of artificial intelligence for process optimization.

The increasing burden of chronic and infectious diseases is expected to drive the growth of the mRNA therapeutics CDMO market in the coming years. Chronic and infectious diseases include long-term health conditions such as diabetes, cardiovascular diseases, and asthma, as well as infections caused by pathogens like viruses, bacteria, and parasites that can be transmitted among individuals. This rise is primarily attributed to aging populations, which are more vulnerable to both chronic illnesses and infections. mRNA therapeutics CDMOs support efforts to combat these conditions by offering comprehensive development and manufacturing services that accelerate the delivery of targeted, personalized mRNA treatments. For example, in April 2024, Allergy UK, a UK-based national charity, reported that more than 21 million people in the UK were affected by allergies, making them the most commonly reported chronic condition in 2022. Projections suggest that by 2026, half of Europe's population will experience at least one allergy. Consequently, the growing burden of chronic and infectious diseases is contributing to the expansion of the mRNA therapeutics CDMO market.

Leading companies in the mRNA therapeutics CDMO market are concentrating on innovative developments such as in situ nanomedicine vaccines to enhance the precision and effectiveness of mRNA-based treatments through targeted immune responses. An in situ nanomedicine vaccine represents a next-generation mRNA therapeutic that facilitates the internal generation of nanomedicines within the patient's body. This enables highly targeted delivery and custom immune activation through engineered transgene expression. For instance, in January 2025, Esphera SynBio Inc., a biotechnology company based in Canada, launched a new initiative backed by the CQDM Quantum Leap program. The project seeks to improve first-generation lipid nanoparticle/mRNA vaccines by introducing proprietary transgene designs that enable in vivo production of immunostimulatory nanomedicines. This strategy enhances antigen targeting and allows for customized immune responses, representing a potential breakthrough in vaccine development.

In September 2024, Agilent Technologies Inc., a US-based medical equipment company, acquired BIOVECTRA for $0.925 billion. The acquisition is intended to strengthen Agilent's CDMO capabilities in emerging therapeutic areas, particularly mRNA-based treatments, by incorporating BIOVECTRA's specialized knowledge in biologics and advanced pharmaceutical manufacturing. BIOVECTRA is a Canada-based contract development and manufacturing organization focused on mRNA therapeutics and related modalities.

Major players in the mRNA therapeutics CDMO market are Sanofi SA, Thermo Fisher Scientific Inc., Boehringer Ingelheim, Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, BioNTech SE, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Novo Holdings AS, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., CureVac SE, TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG, and RiboPro.

North America was the largest region in the mRNA therapeutics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mRNA therapeutics CDMO report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the mRNA therapeutics CDMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mRNA therapeutics CDMO market consists of revenues earned by entities by providing services such as supply chain management, cold chain logistics, quality assurance auditing, clinical trial material preparation, batch release testing, serialization, and packaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The mRNA therapeutics CDMO market also includes sales of products such as lipid excipients, nucleotide reagents, capping analogs, custom RNA oligonucleotides, and modified nucleosides. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

mRNA Therapeutics CDMO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mrna therapeutics cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mrna therapeutics cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mrna therapeutics cdmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type Of Service: Development Services; Manufacturing Services; Laboratory Services
2) By Indication: Infectious Diseases; Metabolic And Genetic Diseases; Cardiovascular And Cerebrovascular Diseases
3) By Application: Viral Vaccines; Protein Replacement Therapies; Cancer Immunotherapies
4) By End User: Pharmaceutical Companies; Biotechnology Companies; Academic Institutions; Research Organizations
Subsegments:
1) By Development Services: Process Development; Analytical Method Development; Formulation Development; Regulatory Support
2) By Manufacturing Services: Plasmid DNA Manufacturing; mRNA Synthesis; Lipid Nanoparticle (LNP) Formulation; Fill-Finish Services
3) By Laboratory Services: Quality Control Testing; Stability Testing; Bioanalytical Testing; Preclinical Testing
Companies Mentioned: Sanofi SA; Thermo Fisher Scientific Inc.; Boehringer Ingelheim; Danaher Corporation; Merck KGaA; FUJIFILM Holdings Corporation; Evonik Industries AG; BioNTech SE; AGC Biologics GmbH; Eurofins Scientific SA; Samsung Biologics Co. Ltd.; Wuxi Biologics; Recipharm AB; EMERGENT BioSolutions Inc.; Genscript Biotech; Novo Holdings AS; Ginkgo Bioworks Holdings Inc.; Corden Pharma Corp.; CureVac SE; TriLink BioTechnologies LLC; Biocina Pty Ltd.; Aldevron LLC; Synbio Technologies LLC; etherna manufacturing; Bio-Synthesis Inc.; Biomay AG; RiboPro
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37070

1. Executive Summary

2. mRNA Therapeutics CDMO Market Characteristics

3. mRNA Therapeutics CDMO Market Trends And Strategies

4. mRNA Therapeutics CDMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global mRNA Therapeutics CDMO Growth Analysis And Strategic Analysis Framework

5.1. Global mRNA Therapeutics CDMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global mRNA Therapeutics CDMO Market Growth Rate Analysis
5.4. Global mRNA Therapeutics CDMO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global mRNA Therapeutics CDMO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global mRNA Therapeutics CDMO Total Addressable Market (TAM)

6. mRNA Therapeutics CDMO Market Segmentation

6.1. Global mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Development Services
Manufacturing Services
Laboratory Services
6.2. Global mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Infectious Diseases
Metabolic And Genetic Diseases
Cardiovascular And Cerebrovascular Diseases
6.3. Global mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Viral Vaccines
Protein Replacement Therapies
Cancer Immunotherapies
6.4. Global mRNA Therapeutics CDMO Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical Companies
Biotechnology Companies
Academic Institutions
Research Organizations
6.5. Global mRNA Therapeutics CDMO Market, Sub-Segmentation Of Development Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Process Development
Analytical Method Development
Formulation Development
Regulatory Support
6.6. Global mRNA Therapeutics CDMO Market, Sub-Segmentation Of Manufacturing Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plasmid DNA Manufacturing
mRNA Synthesis
Lipid Nanoparticle (LNP) Formulation
Fill-Finish Services
6.7. Global mRNA Therapeutics CDMO Market, Sub-Segmentation Of Laboratory Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Quality Control Testing
Stability Testing
Bioanalytical Testing
Preclinical Testing

7. mRNA Therapeutics CDMO Market Regional And Country Analysis

7.1. Global mRNA Therapeutics CDMO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global mRNA Therapeutics CDMO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific mRNA Therapeutics CDMO Market

8.1. Asia-Pacific mRNA Therapeutics CDMO Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China mRNA Therapeutics CDMO Market

9.1. China mRNA Therapeutics CDMO Market Overview
9.2. China mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India mRNA Therapeutics CDMO Market

10.1. India mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan mRNA Therapeutics CDMO Market

11.1. Japan mRNA Therapeutics CDMO Market Overview
11.2. Japan mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia mRNA Therapeutics CDMO Market

12.1. Australia mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia mRNA Therapeutics CDMO Market

13.1. Indonesia mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea mRNA Therapeutics CDMO Market

14.1. South Korea mRNA Therapeutics CDMO Market Overview
14.2. South Korea mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe mRNA Therapeutics CDMO Market

15.1. Western Europe mRNA Therapeutics CDMO Market Overview
15.2. Western Europe mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK mRNA Therapeutics CDMO Market

16.1. UK mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany mRNA Therapeutics CDMO Market

17.1. Germany mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France mRNA Therapeutics CDMO Market

18.1. France mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy mRNA Therapeutics CDMO Market

19.1. Italy mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain mRNA Therapeutics CDMO Market

20.1. Spain mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe mRNA Therapeutics CDMO Market

21.1. Eastern Europe mRNA Therapeutics CDMO Market Overview
21.2. Eastern Europe mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia mRNA Therapeutics CDMO Market

22.1. Russia mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America mRNA Therapeutics CDMO Market

23.1. North America mRNA Therapeutics CDMO Market Overview
23.2. North America mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA mRNA Therapeutics CDMO Market

24.1. USA mRNA Therapeutics CDMO Market Overview
24.2. USA mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada mRNA Therapeutics CDMO Market

25.1. Canada mRNA Therapeutics CDMO Market Overview
25.2. Canada mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America mRNA Therapeutics CDMO Market

26.1. South America mRNA Therapeutics CDMO Market Overview
26.2. South America mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil mRNA Therapeutics CDMO Market

27.1. Brazil mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East mRNA Therapeutics CDMO Market

28.1. Middle East mRNA Therapeutics CDMO Market Overview
28.2. Middle East mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa mRNA Therapeutics CDMO Market

29.1. Africa mRNA Therapeutics CDMO Market Overview
29.2. Africa mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa mRNA Therapeutics CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. mRNA Therapeutics CDMO Market Competitive Landscape And Company Profiles

30.1. mRNA Therapeutics CDMO Market Competitive Landscape
30.2. mRNA Therapeutics CDMO Market Company Profiles
- 30.2.1. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Boehringer Ingelheim Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

31. mRNA Therapeutics CDMO Market Other Major And Innovative Companies

31.1. FUJIFILM Holdings Corporation
31.2. Evonik Industries AG
31.3. BioNTech SE
31.4. AGC Biologics GmbH
31.5. Eurofins Scientific SA
31.6. Samsung Biologics Co. Ltd.
31.7. Wuxi Biologics
31.8. Recipharm AB
31.9. EMERGENT BioSolutions Inc.
31.10. Genscript Biotech
31.11. Novo Holdings AS
31.12. Ginkgo Bioworks Holdings Inc.
31.13. Corden Pharma Corp.
31.14. CureVac SE
31.15. TriLink BioTechnologies LLC

32. Global mRNA Therapeutics CDMO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The mRNA Therapeutics CDMO Market

34. Recent Developments In The mRNA Therapeutics CDMO Market

35. mRNA Therapeutics CDMO Market High Potential Countries, Segments and Strategies

35.1 mRNA Therapeutics CDMO Market In 2029 - Countries Offering Most New Opportunities
35.2 mRNA Therapeutics CDMO Market In 2029 - Segments Offering Most New Opportunities
35.3 mRNA Therapeutics CDMO Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer